Beyond Diabetes: Abbott Launches Glucose Sport Biosensor For Athletes To Track Blood Sugar
Analyst Larry Biegelsen expects Abbott’s CGM move into the consumer market could open a large new marketing opportunity.
You may also be interested in...
The market for blood glucose monitoring devices is expected to see double-digit growth, reaching $19.7bn by 2025. This growth is driven largely by the rising demand for smaller, more convenient continuous glucose monitoring (CGMs) devices with improved digital capabilities.
The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the second day of the meeting.
Abbott reported strong sales for diagnostics and devices in the third quarter and raised its full-year EPS guidance to $3.55 per share.